FY2025 · period end Dec '25 · from the 10-K filed Feb 17, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B |
| Gross Profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B |
| Operating Income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B |
| Net Income | — | — | — | — | — |
| EPS (Diluted) | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $24.47B | $22.00B | $19.53B | $17.57B | $16.62B |
| Cash & Equivalents | $1.97B | $0.41B | $0.86B | $0.93B | $1.93B |
| Total Debt | $11.14B | $8.97B | $8.57B | $8.91B | $8.80B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.53B | $3.44B | $2.50B | $1.53B | $1.87B |
| Capital Expenditures | $0.88B | $0.79B | $0.71B | $0.59B | $0.55B |
| Free Cash Flow | $3.66B | $2.65B | $1.79B | $0.94B | $1.32B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% |
| Operating Margin | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% |
| Net Margin | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Return on Equity | 16.7% | 14.0% | 12.6% | 12.3% | 13.6% |
| Return on Assets | 9.3% | 7.8% | 6.9% | 6.5% | 6.9% |
| Debt / Equity | 0.46× | 0.41× | 0.44× | 0.51× | 0.53× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000885725-26-000041 | May 18, 2026 | May 18, 2026 | May 18, 2026 11:15 UTC | EDGAR |
| 8-K | 0000885725-26-000042 | May 18, 2026 | May 18, 2026 | May 18, 2026 11:17 UTC | EDGAR |
| 8-K | 0000885725-26-000036 | Apr 30, 2026 | May 5, 2026 | May 5, 2026 20:47 UTC | EDGAR |
| 10-Q | 0000885725-26-000033 | Mar 31, 2026 | May 1, 2026 | May 1, 2026 10:25 UTC | EDGAR |
| 8-K | 0000885725-26-000031 | Apr 22, 2026 | Apr 22, 2026 | Apr 22, 2026 10:34 UTC | EDGAR |
| 8-K | 0000885725-26-000029 | Mar 28, 2026 | Mar 30, 2026 | Mar 30, 2026 10:14 UTC | EDGAR |
| 8-K | 0000885725-26-000017 | Feb 26, 2026 | Feb 26, 2026 | Feb 26, 2026 22:11 UTC | EDGAR |
| 8-K | 0000885725-26-000013 | Feb 18, 2026 | Feb 23, 2026 | Feb 23, 2026 21:33 UTC | EDGAR |
Direct links to SEC EDGAR. BSX has additional filings available on the SEC site.
6 numbers BOSTON SCIENTIFIC CORP later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·Q3 2017
Major restatementwas$554M
Revised up in a 10-Q. Any P/OCF built on the original was 25.3% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2016
Major restatementwas$972M
Revised up in a 10-K. Any P/OCF built on the original was 17.8% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2015
Major restatementwas$600M
Revised up in a 10-K. Any P/OCF built on the original was 13.2% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2013
Major restatementwas$163M
Revised up in a 10-Q. Any P/OCF built on the original was 12.8% too high.
Operating Income (Loss)·FY 2015
Major restatementwas-$327M
Revised up in a 10-K.
Revenues·Q2 2016
Notable restatementwas$2.3B
Revised down in a 10-Q. Any P/S built on the original was 7.6% too low.
BSX is not the only one.
See every restatement we've found across the market — or get an alert the next time BSX revises a number.
Restatements are detected by comparing every vintage of a fact across all of BOSTON SCIENTIFIC CORP's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BSX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling BOSTON SCIENTIFIC CORP — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BSX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on BSX and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs